Royalty Report: Pain, Drugs, Pharmaceuticals – Collection: 26321


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Pain
  • Drugs
  • Pharmaceuticals
  • Therapeutic
  • Disease
  • Delivery
  • Personal Care Products
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26321

License Grant
The Licensor signed a License Agreement with the Licensee for Indaflex.

Under the terms of the Agreement executed the Licensor could receive up to $116 million in milestone payments on achievement of all regulatory and revenue targets. In addition the Licensee assumes all clinical and commercialization costs, in return for full commercialization and sub-licensing rights in the U.S and other regions.

License Property
Indaflex(TM) is topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation intended to start clinical development soon for use in the treatment symptoms of arthritis.  The product is currently in Phase II clinical development for the reduction of signs and symptoms associated with osteoarthritis of the knee.

Indaflexâ„¢ Cream is a semi-solid formulation for topical administration, containing the active ingredient Indomethacin, at a concentration of 2.5%. Indaflexâ„¢ Cream is an innovative oil-in-water emulsion formulation. There are three main features of this product which contribute to its improved efficacy as a topical analgesic drug loading/concentration, a nanoparticulate oil-in-water emulsion formulation and an improved partitioning of lipophilic drug from nanoparticles into the lipid matrix of the absorbing tissue.

Indaflexâ„¢ Cream is composed of a highly dispersed colloidal suspension of nano-sized oil droplets, loaded with active drug and suspended in an aqueous phase.

Field of Use
Indaflex is a non-steroidal anti-inflammatory drug, typically prescribed in order to manage symptoms such as pain, fever, swelling and stiffness. This medication acts as an inhibitor of prostaglandin production – prostaglandins are the agents that are known to induce these symptoms.

IPSCIO Record ID: 26558

License Grant
The Mexican Licensee has the Exclusive and non-transferable manufacturing rights and distribution rights in Mexico for Indaflex.
License Property
A Canadian pharma Licensed Indaflex, a lead pharmaceutical product under development for commercialization in Mexico. Licensor owns and/or has rights to the Intellectual Property Rights  relating to a pharmaceutical agent for pain control and inflammation treatment;

Indaflex is a topical NSAID formulation intended to be used in the treatment of arthritis. Indaflex is our only prescription drug at the clinical trial stage.

Field of Use
Field of Use relates to the medical industry.

IPSCIO Record ID: 27649

License Grant
Licensor grants an exclusive license, with the right to grant sublicenses under the licensed technology to make, use, have made, sell, offer for sale, import and export products.

Licensor grants a license to use the house marks in connection with the commercialization of the products.

License Property
The licensed technology is US patent 6926907 and filed patent serial no. 11/129,320, pharmaceutical compositions for the coordinated delivery of NSAIDs.

NSAID means any non-steroidal anti-inflammatory drug, the primary mechanism of action of which is inhibition of cyclooxygenase, but excluding acetyl salicylic acid.

Field of Use
The field of use is the treatment of human diseases and conditions by means of a pharmaceutical product.

IPSCIO Record ID: 6681

License Grant
The British Virgin Island Licensor hereby grants to the Hong Kong Licensee, an equally-owned joint-venture,  exclusive and non-transferable Manufacturing Rights and Distribution Rights for the Products and to use the Intellectual Property Rights in each Country in the Territory for the duration of the Term to the extent required to practice the exclusive rights granted herein to the Products, provided such Products conform to the Standards of Quality defined in the Agreement.
License Property
LIST OF PRODUCTS  1% Indaflex (1% Indomethacin); 1% Diclofenac; Flexogan (6% Menthol, 6% Camphor, 16% Methyl Salicylate).  Flexogan is an over-the-counter, deep penetrating topical cream that provides temporary relief from pain associated with joints, muscles and minor arthritis.

Chinese Patent Application No. 03165005.8 Title Vehicle for Topical deliver of Anti-Inflammatory Compounds.

Field of Use
Field means the use of the Products in pain management and inflammation treatment.

IPSCIO Record ID: 282791

License Grant
The original agreement for commercialization of ConsensiTM in the U.S has been amended to include creating a near-term revenue streams to support further development of our oncology pipeline, engage a distribution partner with an established sales network and access to thousands of pharmacies to drive the launch of the drug.  In addition, a marketing plan and pricing strategy have been finalized.
License Property
Licensor is a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance.

ConsensiTM is a fixed-dose combination of celecoxib, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate, a drug designed to treat hypertension.

ConsensiTM is a fixed-dose combination of celecoxib, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate, a drug designed to treat hypertension.

Field of Use
The Indications and Usage for Consensiâ„¢ is a combination of amlodipine besylate, a calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID), indicated for patients for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Lowering blood pressure reduces the risk of fatal and nonfatal CV events, primarily strokes and myocardial infarctions.

IPSCIO Record ID: 28144

License Grant
The Licensee entered into a binding memorandum of understanding the Israeli Licensor, the technology transfer company of the University, regarding certain patents in connection with nanoparticles for topical delivery of the Licensee's neuropathic pain drug candidate ready for a Phase III clinical trial. The parties will be entered into a definitive license agreement within six months of the date of the MOU for the commercial development and marketing of the Technology worldwide.
License Property
The Licensor's patents in connection with nanoparticles for topical delivery for the Licensee's neuropathic pain drug candidate.
Field of Use
The pain compound AmiKetâ„¢, a topical cream consisting of a patented combination of amitriptyline and ketamine that is in late stage development for the treatment of peripheral neuropathies and has received Orphan Drug Designation for Post Herpetic Neuralgia.

IPSCIO Record ID: 319516

License Grant
Licensee entered into an exclusive global license and sub-license from the Israel Licensor for the rights to discover, make, sell, market, and otherwise commercialize Licensed Compound or any pharmaceutical composition or preparation (in any and all dosage forms) in final form, including any combination product, containing a Licensed Compound (Licensed Product).
License Property
Licensed Compound means bupivacaine liposome, in injectable gel or suspension.

Licensed Product means any pharmaceutical composition or preparation (in any and all dosage forms) in final form such as LBL100 or ProbudurTM.

LBL100 or ProbudurTM means Long-acting Bupivacaine Liposomal-gel 3.0% which is a drug product candidate based on a unique liposomal delivery system utilizing large multi-vesicular vesicles (“LMVVs”) encapsulating a high dose of the local anesthetic bupivacaine. These drug-loaded liposomes are composed of lecithin and cholesterol which are generally recognized as safe (“GRAS”) by the FDA. These LMVVs are embedded in hydrogel beads to form a Lipogel. The system delivers a local anesthetic/analgesic medicine from the Lipogel. This this product candidate could potentially eliminate the need for opioids for post-operative pain relief.

Probudur is the product candidate covered by US Patent No. 9,713,591. The patent contains composition claims to pharmaceutical compositions having an external storage solution containing an active pharmaceutical ingredient and particles of liposomes embedded in a polymeric matrix contained within the storage solution.

9,713,591 – Composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same

Licensor develops a number of highly-potent therapeutics utilizing proprietary liposome-based nano-drugs with novel drug-loading-capabilities and drug-release mechanisms. Licensors proprietary platform implements a highly-efficient innovative approach which allows for the remote drug loading into nano-liposomes and concomitant controlled release of the drugs at the targeted site.

Field of Use
The field of use is for the treatment of pain control to be used for general surgeons, anesthesiologists, and orthopedic surgeons. Probudur may provide pain control for up to 96 hours.

LBL100 (3% bupivacaine in Lipogel), is being developed as a long-acting local anesthetic for post-operative pain.

LBL100 is a drug product based on a type of liposomal delivery system with large multi-vesicular vesicles (LMVVs) encapsulating a very high dose of the local anesthetic bupivacaine in a unique way. These drug-loaded liposomes are composed of lecithin and cholesterol; both lipids are “GRAS” (Generally Recognized As Safe). These LMVVs are embedded in hydrogel beads to form a lipogel. The system delivers a local analgesic medicine from the Lipogel that is intended to provide improved onset, duration and peak performance properties. With early studies indicating it can provide pain control for up to 96 hours, the formulation has shown the potential to reduce reliance on opioid pain management to improve quality of care and hospital economics.

IPSCIO Record ID: 319352

License Grant
Licensor (of the United Kindgom) granted Licensee the exclusive global rights to discover, develop, make, sell, market, and otherwise commercialize any pharmaceutical composition or preparation (in any and all dosage forms) in final form containing one or more compounds, including Epoladerm and OSF200, that was developed, manufactured or commercialized utilizing Licensor’s spray formulation technology (Licensor Product), to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses).
License Property
Topical Spray Technology product mean DSF100 or EpoladermTM and OSF200, a topical nonsteroidal anti-inflammatory drug. This Technology is a therapeutic treatment for topicals and transdermal deliveries due to its adhesion and accessibility properties, especially around joints and curved body surfaces.

OSF200 – for chronic osteoarthritis of the knee
DSF100 or EpoladermTM – for acute musculoskeletal pain

The product candidate is covered by US Patent No. 8,349,297. The patents contain broad composition claims to a platform of pharmaceutical formulations which form a film on spray administration where the active agent is present at least 80% saturation and there is no undissolved active agent in the formulation. The claims also include a method of treatment and an aerosol dispenser containing the formulation.

8,349,297 – Topical formulations

Field of Use
The field of use is for the treatment of pain to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses) and not limited to, treatment of estrogen levels, Alzheimer’s disease, dementia, Parkinson’s disease, neuropathic issues, and acute and chronic pain such as acute musculoskeletal pain and chronic osteoarthritis of the knee.

IPSCIO Record ID: 234734

License Grant
The Israel Licensor granted exclusive rights to import, manufacture and distribute its lead drug candidate, Consensiâ„¢, in China to the Chinese Licensee.
License Property
Consensi™, formerly known as KIT-302, is a combination drug intended to simultaneously treat pain caused by osteoarthritis, and hypertension, which is a common side effect of stand-alone drugs that treat osteoarthritis pain. Consensi™ is comprised of two FDA-approved drugs, celecoxib (Celebrex®), a non-steroidal anti-inflammatory COX-2 inhibitor (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a calcium channel blocker for lowering blood pressure.
Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.